Aims and Background: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone- refractory prostate cancer (mHRPC). Methods: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints. Results: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients (50%). Severe neutropenia was reported in 12.5% of patients. Conclusions: Treatment with docetaxel every three weeks is an effective and well tolerated therapeutic option in patients with mHRPC.

Cicero, G., & De Luca, R. (2011). Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an italian clinical axperience. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 15, 325-331.

Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an italian clinical axperience

CICERO, Giuseppe;DE LUCA, Rossella
2011

Abstract

Aims and Background: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone- refractory prostate cancer (mHRPC). Methods: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints. Results: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients (50%). Severe neutropenia was reported in 12.5% of patients. Conclusions: Treatment with docetaxel every three weeks is an effective and well tolerated therapeutic option in patients with mHRPC.
Settore MED/06 - Oncologia Medica
Cicero, G., & De Luca, R. (2011). Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an italian clinical axperience. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 15, 325-331.
File in questo prodotto:
File Dimensione Formato  
912.pdf

accesso aperto

Descrizione: articolo
Dimensione 83.69 kB
Formato Adobe PDF
83.69 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/58516
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 4
social impact